| Combination of | |
|---|---|
| Aclidinium bromide | Long-acting muscarinic antagonist |
| Formoterol | Long-acting β2 agonist |
| Clinical data | |
| Trade names | Brimica Genuair, Duaklir Genuair, Duaklir Pressair |
| AHFS/Drugs.com | Professional Drug Facts |
| License data | |
| Pregnancy category |
|
| Routes of administration | Inhalation |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| KEGG | |
Aclidinium bromide/formoterol, sold under the brand names Duaklir and Brimica, is a fixed-dose combination medication for inhalation, used in the management of chronic obstructive pulmonary disease (COPD).[5] It consists of aclidinium bromide, a long-acting muscarinic antagonist, and formoterol, a long-acting β2 agonist.[3][4]
References
- ^ "Duaklir Genuair 340 micrograms /12 micrograms inhalation powder - Summary of Product Characteristics (SmPC)". (emc). 9 September 2019. Archived from the original on 26 July 2020. Retrieved 26 July 2020.
- ^ "Duaklir Pressair- aclidinium bromide and formoterol fumarte powder, metered". DailyMed. 3 July 2020. Retrieved 28 November 2020.
- ^ a b "Duaklir Genuair EPAR". European Medicines Agency (EMA). Retrieved 26 July 2020.
- ^ a b "Brimica Genuair EPAR". European Medicines Agency (EMA). Retrieved 26 July 2020.
- ^ D'Urzo AD, Singh D, Donohue JF, Chapman KR, Wise RA (September 2021). "Aclidinium bromide/formoterol fumarate as a treatment for COPD: an update". Expert Review of Respiratory Medicine. 15 (9): 1093–1106. doi:10.1080/17476348.2021.1920403. PMID 34137664. S2CID 235460050.
External links
- "Aclidinium bromide". Drug Information Portal. U.S. National Library of Medicine.
- "Formoterol fumarate". Drug Information Portal. U.S. National Library of Medicine.
 | This drug article relating to the respiratory system is a stub. You can help Wikipedia by expanding it. |
This page was last edited on 20 December 2023, at 19:20